Two schedules of etirinotecan pegol (NKTR-102) in patients with previously treated metastatic breast cancer: a randomised phase 2 study.

[1]  J. Lubiński,et al.  Preliminary safety and activity results of trabectedin in a phase II trial dedicated to triple-negative (ER-, PR-, HER2-), HER2+++, or BRCA1/2 germ-line-mutated metastatic breast cancer (MBC) patients (pts). , 2016, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[2]  J. Harvey,et al.  Breast cancer—facts and figures , 2013 .

[3]  M. Borad,et al.  A Multicenter, Phase I, Dose-Escalation Study to Assess the Safety, Tolerability, and Pharmacokinetics of Etirinotecan Pegol in Patients with Refractory Solid Tumors , 2012, Clinical Cancer Research.

[4]  Chris Twelves,et al.  Eribulin monotherapy versus treatment of physician's choice in patients with metastatic breast cancer (EMBRACE): a phase 3 open-label randomised study , 2011, The Lancet.

[5]  R. Paridaens,et al.  Phase II study of the halichondrin B analog eribulin mesylate in patients with locally advanced or metastatic breast cancer previously treated with an anthracycline, a taxane, and capecitabine. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[6]  H. Iwata,et al.  Phase III randomized trial of sunitinib versus capecitabine in patients with previously treated HER2-negative advanced breast cancer , 2010, Breast Cancer Research and Treatment.

[7]  E. Perez,et al.  Efficacy of ixabepilone in ER/PR/HER2-negative (triple-negative) breast cancer , 2010, Breast Cancer Research and Treatment.

[8]  J. Jassem,et al.  Activity of ixabepilone in oestrogen receptor-negative and oestrogen receptor-progesterone receptor-human epidermal growth factor receptor 2-negative metastatic breast cancer. , 2009, European journal of cancer.

[9]  Eric Sauerbrei,et al.  Randomized phase II study comparing two schedules of everolimus in patients with recurrent/metastatic breast cancer: NCIC Clinical Trials Group IND.163. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[10]  D. V. Hoff,et al.  8015 NKTR-102 demonstrates nonclinical and phase 1 clinical anti-tumor activity in ovarian cancer , 2009 .

[11]  David A. Smith,et al.  Phase II study of eribulin mesylate, a halichondrin B analog, in patients with metastatic breast cancer previously treated with an anthracycline and a taxane. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[12]  J. Sparano,et al.  Ixabepilone plus capecitabine improves progression free survival in patients with metastatic breast cancer resistant to taxanes: a pooled analysis from two phase III trials. , 2009 .

[13]  M. Borad,et al.  595 POSTER First Phase I trial of NKTR-102 (PEG-irinotecan) reveals early evidence of broad anti-tumor activity in three schedules , 2008 .

[14]  M. Eldon,et al.  NKTR-102, a novel PEGylated-irinotecan, has a superior acute safety and tolerability profile compared to irinotecan in rats and dogs , 2008 .

[15]  H. Rugo,et al.  Phase II study of sunitinib malate, an oral multitargeted tyrosine kinase inhibitor, in patients with metastatic breast cancer previously treated with an anthracycline and a taxane. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[16]  N. Robert,et al.  Phase II study of weekly albumin-bound paclitaxel for patients with metastatic breast cancer heavily pretreated with taxanes. , 2007, Clinical breast cancer.

[17]  M. Bentley,et al.  Polyethylene glycol conjugation of irinotecan improves its antitumor activity in three mouse xenograft models , 2007 .

[18]  M. Bentley,et al.  727 POSTER PEGylation governs the disposition and metabolism of irinotecan following administration of a novel PEG–Irinotecan conjugate , 2007 .

[19]  M. Bentley,et al.  722 POSTER Antitumor activity and pharmacokinetics of a novel PEGylated irinotecan in irinotecan-resistant colorectal tumours implanted in mice , 2007 .

[20]  S. Steinberg,et al.  Phase II trial of ixabepilone, an epothilone B analog, in patients with metastatic breast cancer previously untreated with taxanes. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[21]  J. Baselga,et al.  Phase II clinical trial of ixabepilone (BMS-247550), an epothilone B analog, in patients with taxane-resistant metastatic breast cancer. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[22]  E. Perez,et al.  Efficacy and safety of ixabepilone (BMS-247550) in a phase II study of patients with advanced breast cancer resistant to an anthracycline, a taxane, and capecitabine. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[23]  D. Richel,et al.  A randomised phase II multicentre trial of irinotecan (CPT-11) using four different schedules in patients with metastatic colorectal cancer , 2004, British Journal of Cancer.

[24]  E. Perez,et al.  Randomized phase II study of two irinotecan schedules for patients with metastatic breast cancer refractory to an anthracycline, a taxane, or both. , 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[25]  M. Christian,et al.  [New guidelines to evaluate the response to treatment in solid tumors]. , 2000, Bulletin du cancer.

[26]  E. Perez,et al.  Phase II trial of sorafenib in patients with metastatic breast cancer previously exposed to anthracyclines or taxanes: North Central Cancer Treatment Group and Mayo Clinic Trial N0336. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.